Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases

Jagadeshwar G. Reddy, Edward V. Loftus

Research output: Contribution to journalReview article

71 Scopus citations

Abstract

In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.

Original languageEnglish (US)
Pages (from-to)837-855
Number of pages19
JournalGastroenterology Clinics of North America
Volume35
Issue number4
DOIs
StatePublished - Dec 1 2006

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases'. Together they form a unique fingerprint.

  • Cite this